March 29, 2011 - CIT, a leading European non-clinical CRO specialized in health and safety research, announces a new range of fast and economical services to meet the growing needs of companies developing the drugs of tomorrow. The services, grouped under the name LeadScreen™, offer an extensive array of tests designed to give an early evaluation of safety of drugs thought to have development potential.Currently, around 20 per cent of candidate drugs fail during standard regulatory nonclinical studies, too often due to late identification of toxicological effects. Using CIT’s LeadScreen™, the early detection of potential toxicity can significantly increase the chances of success when the candidate drug goes through the later stages of non-clinical development. The speed, competitive price and efficacy of LeadScreen™ offers the ability to reduce considerably the financial cost and time associated with standard drug development practices.
The new LeadScreen™ services are fast. From the start of the study to delivery of the results takes only 14 days - a real competitive advantage over tests currently on the market. As well as saving time, LeadScreen™ presents other advantages such as its requirement for only a small quantity of the compound - and attractive pricing...
[...]
...About CIT
CIT is a science-driven, independent, non-clinical contract research organization (CRO) specialized in safety and health research. Founded in 1969, CIT has carried out a vast number of projects for international companies on human and veterinary pharmaceuticals, biotechnology, chemicals, agrochemicals and consumer products. It has contributed to many product registrations around the world. With a staff of 360, CIT offers a full range of research in general toxicology, reproductive toxicology, carcinogenicity, pharmacokinetics and safety pharmacology... [PDF] CIT's Press Release - PDF du communiqué de presse CIT -
